Table 1.
Clinical characteristics of the 57 included patients with systemic lupus erythematosus (SLE).
| Variable | Median (range) or frequency (%) |
|---|---|
| Age (years) | 43 (23–63) |
| Females | 50 (88) |
| Disease duration (years) | 8 (1–35) |
| SLEDAI-2K | 2 (0–8) |
| 1982 ACR criteria fulfilled (number) | 5 (3–9) |
| Ever (current or prior) tobacco smoker | 14 (25) |
| 1982 ACR criteria fulfilled: | |
| ACR 1: malar rash | 23 (40) |
| ACR 2: discoid lupus | 2 (3.5) |
| ACR 3: photosensitivity | 26 (46) |
| ACR 4: oral ulcers | 13 (23) |
| ACR 5: arthritis | 45 (79) |
| ACR 6: serositis | 22 (39) |
| ACR 7: renal disorder | 19 (33) |
| ACR 8: neurologic disorder | 6 (11) |
| ACR 9: hematologic disorder | 38 (67) |
| ACR 10: immunologic disorder | 35 (61) |
| ACR 11: antinuclear antibodies | 57 (100) |
| Ongoing immunomodulation: | |
| Antimalarials | 51 (90) |
| Prednisolone | 30 (53) |
| Prednisolone dose (mg/day) | 2.5 (0–15) |
| Mycophenolate mofetil | 15 (26) |
| Methotrexate | 5 (8.8) |
| Azathioprine | 3 (5.3) |
| Other DMARDs/biologics | 8 (14) |
| a CRP genotype (rs1205) | |
| Two major alleles (GG) | 24 (44) |
| One minor allele (AG) | 23 (42) |
| Two minor alleles (AA) | 8 (15) |
a
Genotype analysis available for 55 patients.
ACR, American College of Rheumatology; DMARDs, disease-modifying anti-rheumatic drugs; SLEDAI-2K, SLE disease activity index 2000.